🇺🇸 FDA
Pipeline program

BinD19

2017ZDYFY-BinD19

Phase 2 mab active

Quick answer

BinD19 for Relapsed B-cell Acute Lymphoblastic Leukemia is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Relapsed B-cell Acute Lymphoblastic Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials